CMG
67
3
DGX
50
2
PM
64
2
FRT
45
6
PWR
72
2
DE
56
10
ADP
66
2
CTSH
54
-2
ROST
52
5
ABT
62
5
PRU
62
5
GOOG
53
-12
BF.B
31
3
PLD
48
-5
PDCO
38
3
STX
56
4
AN
54
4
TRV
56
3
WHR
64
3
EW
39
2
CMG
67
3
DGX
50
2
PM
64
2
FRT
45
6
PWR
72
2
DE
56
10
ADP
66
2
CTSH
54
-2
ROST
52
5
ABT
62
5
PRU
62
5
GOOG
53
-12
BF.B
31
3
PLD
48
-5
PDCO
38
3
STX
56
4
AN
54
4
TRV
56
3
WHR
64
3
EW
39
2
Financhill
Back

Pieris Pharmaceuticals 10K Form

Sell
43

PIRS
Pieris Pharmaceuticals

Last Price:
16.64
Seasonality Move:
14.9%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PIRS News And Ratings

See the #1 stock for the next 7 days that we like better than PIRS

PIRS Financial Statistics

Sales & Book Value

Annual Sales: $42.81M
Cash Flow: $146K
Price / Cash Flow: 0
Annual Sales: $12.32
Price / Book: 1.29

Profitability

EPS (TTM): -12.17000
Net Income (TTM): $-15.95M
Gross Margin: $5.37M
Return on Equity: 0%
Return on Assets: 0%

Pieris Pharmaceuticals Earnings Forecast

Key Pieris Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 2 years for PIRS is 118.42%.
  • The Selling, General & Administrative Expenses for PIRS have been equal to 39.37% of Gross Profit Margin.
  • The Research & Development expenses have been 97.64% of Revenue.
  • The Interest Expense is -1.28% of Operating Income.
  • The Net Earning history of PIRS is -57.33% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 4 years.

Pieris Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PIRS
CUSIP: 720795
Website: pieris.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PIRS Technical Analysis vs Fundamental Analysis

Sell
43
Pieris Pharmaceuticals (PIRS) is a Sell

Is Pieris Pharmaceuticals a Buy or a Sell?